ArticleFrontiers in immunology2026
Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is the most common malignant neoplasm in women worldwide and in Peru. Beyond hormonal and genetic factors, cytokines play a key role in tumor aggressiveness and therapeutic resistance. However, evidence on circulating cytokine profiles in Latin American populations is limited. Objective: We aimed to characterize the plasma cytokine profile in Peruvian women with BC and evaluate its association with molecular subtypes and treatment response. Materials and methods: A prospective cohort study was conducted. We included 88 BC patients with clinical stage II-III, who were diagnosed at three different cancer centers in Peru: Instituto Nacional de Enfermedades Neoplásicas (INEN, Lima-Peru), Instituto Regional de Enfermedades Neoplásicas del Norte (IREN-NORTE, Trujillo-Peru), and Instituto Regional de Enfermedades Neoplásicas del Sur (IREN-SUR, Arequipa-Peru). Plasma samples were obtained prior to any treatment being administered and underwent analysis using the Bio-Plex Pro™ Human Cytokine 48-Plex Screening Panel kit. Poisson regression models were used to evaluate the association between cytokine levels and complete pathological response (pCR) and clinical response. Results: Cytokine concentration differences in MIP-1β, IL-9, GRO-α, and TNF-β were observed between BC molecular subtypes. Furthermore, lower levels of circulating FGF BASIC appear necessary to increase the relative risk of achieving pCR (RR = 0.9779; 95% CI 0.9573-0.9989; p=0.0392). Decreased levels of FGF BASIC, PDGF BB, SDF-1, IL-12 P40, and IL-8 were also found to be related to an increased chance of clinical responses to treatments. Multivariable analyses indicated that only FGF-BASIC, PDGF-BB, and IL-12 P40 remained independently associated with clinical response. Conclusions: Our study identified plasma cytokines linked to BC subtypes and treatment response in a Peruvian cohort. FGF-BASIC consistently demonstrated a significant association with both pCR and clinical response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.